Article Details
Retrieved on: 2020-12-06 18:00:00
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
New Data Demonstrate <b>Long</b>-<b>Term</b> Benefit of IMBRUVICA® (ibrutinib) as First-Line <b>Treatment</b> for High-Risk Chronic Lymphocytic Leukemia.
Article found on: www.prnewswire.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here